Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

Rhea-AI Summary

Hemogenyx Pharmaceuticals announced total voting rights as of February 28, 2023, confirming the issuance of 1,141,999,321 ordinary shares with a nominal value of 1 pence each. The company holds no treasury shares, resulting in the same number of voting rights available to shareholders. This figure is crucial for shareholders to determine their reporting obligations concerning changes in their shareholdings under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Positive

• Total issued share capital stands at 1,141,999,321 ordinary shares.
• No treasury shares held, allowing full voting rights to all shareholders.

Negative

• None.

Total Voting Rights

LONDON, UK / ACCESSWIRE / February 28, 2023 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 28 February 2022 consists of 1,141,999,321 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 1,141,999,321.

The figure of 1,141,999,321 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com:
https://www.accesswire.com/741104/Hemogenyx-Pharmaceuticals-PLC-Announces-Total-Voting-Rights

FAQ

What are the total voting rights for Hemogenyx Pharmaceuticals as of February 2023?

The total voting rights for Hemogenyx Pharmaceuticals as of February 28, 2023, are 1,141,999,321.

How many ordinary shares does Hemogenyx Pharmaceuticals have?

Hemogenyx Pharmaceuticals has a total of 1,141,999,321 ordinary shares.

What is the significance of the total issued share capital announcement by Hemogenyx?

The announcement helps shareholders calculate their reporting obligations for changes in shareholdings under regulatory rules.

Is Hemogenyx Pharmaceuticals holding any treasury shares?

No, Hemogenyx Pharmaceuticals is not holding any treasury shares.